The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Abstract
BACKGROUND: Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients with chronic myeloid leukemia (CML) in the chronic phase, after failure of imatinib treatment. We assessed the efficacy and safety of dasatinib, as compared with imatinib, for the first-line treatment of chronic-phase CML. METHODS: In a multinational study, 519 patients with newly diagnosed chronic-phase CML were randomly assigned to receive dasatinib at a dose of 100 mg once daily (259 patients) or imatinib at a dose of 400 mg once daily (260 patients). The primary end point was complete cytogenetic response by 12 months, confirmed on two consecutive assessments at least 28 days apart. Secondary end points, including major molecular response, were tested at a significance level of 0.0001 to adjust for multiple comparisons. RESULTS: After a minimum follow-up of 12 months, the rate of confirmed complete cytogenetic response was higher with dasatinib than with imatinib (77% vs. 66%, P=0.007), as was the rate of complete cytogenetic response observed on at least one assessment (83% vs. 72%, P=0.001). The rate of major molecular response was higher with dasatinib than with imatinib (46% vs. 28%, P<0.0001), and responses were achieved in a shorter time with dasatinib (P<0.0001). Progression to the accelerated or blastic phase of CML occurred in 5 patients who were receiving dasatinib (1.9%) and in 9 patients who were receiving imatinib (3.5%). The safety profiles of the two treatments were similar. CONCLUSIONS: Dasatinib, administered once daily, as compared with imatinib, administered once daily, induced significantly higher and faster rates of complete cytogenetic response and major molecular response. Since achieving complete cytogenetic response within 12 months has been associated with better long-term, progression-free survival, dasatinib may improve the long-term outcomes among patients with newly diagnosed chronic-phase CML. (ClinicalTrials.gov number, NCT00481247.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Self-citationLombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291
Self-citationTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,277
Self-citationPrognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
Self-citationHughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Self-citationHasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., & Ansari, H. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.850 · Cited by 819
Self-citationBranford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K. P., & Hughes, T. P. (2002) · Blood · doi:10.1182/blood.v99.9.3472 · Cited by 649
O'Hare, T., Eide, C. A., & Deininger, M. W. N. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 641
Deininger, M., O'Brien, S. G., Guilhot, F., Goldman, J. M., Hochhaus, A., Hughes, T. P., Radich, J. P., Hatfield, A. K., Mone, M., Filian, J., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1126.1126 · Cited by 616
Self-citationde Lavallade, H., Apperley, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G., Bua, M., Szydlo, R., Olavarria, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8154 · Cited by 551
Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 511
Self-citationShah, N. P., Kantarjian, H. M., Kim, D.-W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9260 · Cited by 489
Self-citationHochhaus, A., Baccarani, M., Deininger, M., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., et al. (2008) · Leukemia · doi:10.1038/leu.2008.84 · Cited by 352
Self-citationCortes, J. E., Talpaz, M., O'Brien, S. M., Jones, D. M., Luthra, R., Shan, J., Giles, F. J., Faderl, S. H., Verstovšek, S., Garcia‐Manero, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2139 · Cited by 264
Self-citationShah, N. P., Kim, D.-W., Kantarjian, H., Rousselot, P., Llacer, P. E. D., Enrico, A., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Muller, M. C., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.011452 · Cited by 244
Self-citationResults of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
Cortes, J. E., Jones, D., O'Brien, S., Jabbour, E., Ravandi, F., Koller, C., Borthakur, G., Walker, B., Zhao, W., Shan, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4920 · Cited by 241
Self-citationRoy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J., Larson, R. A., O'Brien, S., So, C., Massimini, G., & Guilhot, F. (2006) · Blood · doi:10.1182/blood-2006-02-001495 · Cited by 216
Quintás-Cardama, A., Kantarjian, H., Jones, D., Shan, J., Borthakur, G., Thomas, D., Kornblau, S., O'Brien, S., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-07-166694 · Cited by 166
Self-citationPorkka, K., Khoury, H. J., PAQUETTE, R. L., Matloub, Y., Sinha, R., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24734 · Cited by 152
Self-citationWhite, D. L., Saunders, V. A., Grigg, A., Arthur, C., Filshie, R., Leahy, M. F., Lynch, K., To, L. B., & Hughes, T. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.9499 · Cited by 74
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationDissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., Kehoe, S. M., Johannessen, C. M., MacConaill, L. E., Hahn, W. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2312 · Cited by 1,005
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-citation
Metadata
- Authors
- Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., Nakamae, H., Huguet, F., Boqué, C., Chuah, C., Bleickardt, E., Bradley-Garelik, M. B., Zhu, C., Szatrowski, T., Shapiro, D., & Baccarani, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-06-17
- Volume
- 362
- Issue
- 24
- Pages
- 2260-2270
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2097799776
- Cited by
- 1,589
- References
- 27
- FWCI
- 107.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.